moatshark My

All holdings

Natera

NTRA

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$442k
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$271.45
+35.7% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-4.7%Q3 ’25
+42.3%Q4 ’25
-12.7%Q1 ’26
+35.7%Q2 ’26
Q3 ’25: -4.7%; Q4 ’25: +42.3%; Q1 ’26: -12.7%; Q2 ’26: +35.7%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Natera.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Natera
Polen Capital Management0.0%$442k$442kAdded +28%5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Natera
Bought or soldFiling
16 Oct 2026Sheena JonathanDirector▼ Sold280$401.29$112kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold280$400.68$112kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold215$399.34$86kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold142$398.95$57kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold98$409.34$40kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold90$404.25$36kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold90$403.70$36kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold80$409.36$33kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold80$406.06$32kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold60$401.62$24kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold50$405.15$20kForm 4
16 Oct 2026Sheena JonathanDirector▼ Sold35$406.63$14kForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold10,321$404.64$4.2mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold6,274$405.18$2.5mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold6,309$402.23$2.5mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold5,974$401.42$2.4mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold3,858$403.27$1.6mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold3,800$407.27$1.5mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold2,671$400.31$1.1mForm 4
15 Oct 2026Rabinowitz MatthewEXECUTIVE CHAIRMAN▼ Sold2,000$408.24$816kForm 4

About the company

Sector
Health care · Services-Medical Laboratories
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
144m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$55.2m2013
$190m2015
$211m2017
$302m2019
$625m2021
$1.1bn2023
$2.3bn2025
2013: $55.2m; 2014: $159m; 2015: $190m; 2016: $217m; 2017: $211m; 2018: $258m; 2019: $302m; 2020: $391m; 2021: $625m; 2022: $820m; 2023: $1.1bn; 2024: $1.7bn; 2025: $2.3bn
Natera revenue and net income by year
YearRevenueNet income
2025$2.3bn−$208m
2024$1.7bn−$190m
2023$1.1bn−$435m
2022$820m−$548m
2021$625m−$472m
2020$391m−$230m
2019$302m−$125m
2018$258m−$128m
2017$211m−$138m
2016$217m−$100m
2015$190m−$70.3m
2014$159m−$5.2m
2013$55.2m−$37.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.